About Aprea AB
|
|
|
1-10 employees
View all
|
|
Pharmaceuticals
|
|
Stockholm, Stockholms Lan
|
|
Aprea AB is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest and KCIF Co-Investment Fund KB.
|
Aprea AB Alternatives
Frequently Asked Questions about Aprea AB
Who is the CEO of Aprea AB?
Claes Post is the CEO of Aprea AB. To contact Claes Post email at [email protected].
Who are the decision makers in Aprea AB?
The decision makers in Aprea AB are Claes Post, Claes Post, etc. Click to Find Aprea AB decision makers emails.
Aprea AB Staff Directory
Search Aprea AB Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Search Portal
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
